These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 7300762)

  • 21. Danger of withdrawal of vasodilator therapy in patients with chronic heart-failure.
    Hanley SP; Cowley A; Hampton JR
    Lancet; 1980 Apr; 1(8171):735-6. PubMed ID: 6103157
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of ambulatory systemic vasodilator therapy with oral prazosin in chronic refractory heart failure. Concomitant relief of pulmonary congestion and elevation of pump output demonstrated by improvements in symptomatology, exercise tolerance, hemodynamics and echocardiography.
    Awan NA; Miller RR; DeMaria AN; Maxwell KS; Neumann A; Mason DT
    Circulation; 1977 Sep; 56(3):346-54. PubMed ID: 884789
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Vasodilator therapy with prazosin for severe congestive heart failure--hemodynamic effects of oral single administration and chronic use (author's transl)].
    Akamatsu T; Suzuki A; Yamamoto T; Takahashi S; Kimata S; Hirosawa K
    Kokyu To Junkan; 1979 Sep; 27(9):991-7. PubMed ID: 538350
    [No Abstract]   [Full Text] [Related]  

  • 24. Hemodynamic effects of captropril in chronic heart failure: efficacy of low-dose treatment and comparison with prazosin.
    Sharpe DN; Coxon R
    Am Heart J; 1982 Nov; 104(5 Pt 2):1164-71. PubMed ID: 6291361
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Heart rate response to oral prazosin in patients with chronic congestive heart failure.
    Elkayam U
    Am J Cardiol; 1980 Oct; 46(4):704. PubMed ID: 7416031
    [No Abstract]   [Full Text] [Related]  

  • 26. Prazosin in the treatment of severe chronic congestive cardiac failure.
    Hockings BE; Cope GD; Clarke GM; Taylor RR
    Aust N Z J Med; 1980 Aug; 10(4):420-5. PubMed ID: 6932833
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Effect of prazosin in therapy-resistant chronic cardiac failure (author's transl)].
    Lemke R; Trompler A; Kaltenbach M; Bussmann WD
    Dtsch Med Wochenschr; 1979 Dec; 104(50):1769-73. PubMed ID: 510213
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Differences in hemodynamic effects of nitroprusside and prazosin in severe chronic congestive heart failure: evidence for a direct negative chronotropic effect of prazosin.
    Packer M; Meller J; Gorlin R; Herman MV
    Am J Cardiol; 1979 Aug; 44(2):310-7. PubMed ID: 463769
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prazosin in the therapy of uncontrolled hypertension.
    Lubbe WF
    S Afr Med J; 1977 Nov; 52(23):913-8. PubMed ID: 339373
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Vasodilator therapy with alpha-receptor blockaders. Acute and chronic effect of prazosin and phentolamine in congestive heart failure].
    Kersting F; Samosny G; Kasper W; Schuster HP
    Med Welt; 1981 Jun; 32(26):1040-5. PubMed ID: 6114383
    [No Abstract]   [Full Text] [Related]  

  • 31. Vasodilator therapy--a physiologic approach to the treatment of heart failure.
    Braunwald E
    N Engl J Med; 1977 Aug; 297(6):331-3. PubMed ID: 876316
    [No Abstract]   [Full Text] [Related]  

  • 32. Hydralazine-induced tachycardia and sodium retention in heart failure. Hemodynamic and symptomatic correction by prazosin therapy.
    Laslett LJ; DeMaria AN; Amsterdam EA; Mason DT
    Arch Intern Med; 1978 May; 138(5):819-20. PubMed ID: 646547
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Acute myocardial infarction with pump failure: hemodynamic response to prazosin].
    Oliveri R; Cremades E; Bazzino O; Doval H
    Cardiology; 1980; 66 Suppl 2():193-201. PubMed ID: 7285030
    [No Abstract]   [Full Text] [Related]  

  • 34. Haemodynamic effects of a single low dose of prazosin in patients with chronic congestive cardiac failure correlations with pharmacokinetics.
    Horowitz JD; Dynon MK; Jarrott B; Brennan JB; Oliver LE; Goble AJ; Louis WJ
    Clin Exp Pharmacol Physiol; 1984; 11(1):7-15. PubMed ID: 6713738
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Plasma renin activity and plasma concentrations of norepinephrine and cyclic nucleotides in heart failure after prazosin.
    Ogasawara B; Ogawa K; Hayashi H; Sassa H
    Clin Pharmacol Ther; 1981 Apr; 29(4):464-71. PubMed ID: 6258839
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Attenuation of prazosin effect on cardiac output in chronic heart failure.
    Arnold SB; Williams RL; Ports TA; Baughman RA; Benet LZ; Parmley WW; Chatterjee K
    Ann Intern Med; 1979 Sep; 91(3):345-9. PubMed ID: 475164
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Potentially deleterious effects of long-term vasodilator therapy in patients with heart failure.
    Young JB; Leon CA; Pratt CM
    Chest; 1987 May; 91(5):737-44. PubMed ID: 3032523
    [No Abstract]   [Full Text] [Related]  

  • 38. Development of pharmacodynamic tolerance to prozosin in congestive heart failure.
    Desch CE; Magorien RD; Triffon DW; Blanford MF; Unverferth DV; Leier CV
    Am J Cardiol; 1979 Nov; 44(6):1178-82. PubMed ID: 495512
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Oral vasodilator therapy with prazosin in severe congestive heart failure.
    Awan NA; Mason DT
    Am Heart J; 1981 May; 101(5):695-700. PubMed ID: 7223616
    [No Abstract]   [Full Text] [Related]  

  • 40. Importance of neuroendocrine regulators of vascular tone and integral adrenoreceptor interaction during oral vasodilator therapy of severe congestive heart failure with prazosin.
    Awan NA; Beattie JM; Evenson ME; Needham KE; Mason DT
    J Cardiovasc Pharmacol; 1982; 4 Suppl 1():S176-80. PubMed ID: 6175836
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.